Research & Literature

Consensus Paper: Neuroimmune Mechanisms of Cerebellar Ataxias.

Mitoma H, Adhikari K, Aeschlimann D, et al.

Cerebellum (London, England) 2016; (15(2)):213-32 doi:10.1007/s12311-015-0664-x.

Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.

Jones AL, Flanagan EP, Pittock SJ, et al.

JAMA neurology 2015; (72(11)):1304-12 doi:10.1001/jamaneurol.2015.2378.

Guidelines for treatment of immune-mediated cerebellar ataxias.

Mitoma H, Hadjivassiliou M, Honnorat J

Cerebellum & ataxias 2015; (2()):14 doi:10.1186/s40673-015-0034-y.

Psychometric Properties of a Core Set of Measures of Balance for People With Cerebellar Ataxia Secondary to Multiple Sclerosis.

Winser S, Smith CM, Hale LA, et al.

Archives of physical medicine and rehabilitation 2017; (98(2)):270-276 doi:10.1016/j.apmr.2016.07.023.

Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review.

Venkatraman A, Opal P

Annals of clinical and translational neurology 2016; (3(8)):655-63 doi:10.1002/acn3.328.

Long term clinical and neurophysiological effects of cerebellar transcranial direct current stimulation in patients with neurodegenerative ataxia.

Benussi A, Dell'Era V, Cotelli MS, et al.

Brain stimulation 2017; (10(2)):242-250 doi:10.1016/j.brs.2016.11.001.

Causes of progressive cerebellar ataxia: prospective evaluation of 1500 patients.

Hadjivassiliou M, Martindale J, Shanmugarajah P, et al.

Journal of neurology, neurosurgery, and psychiatry 2017; (88(4)):301-309 doi:10.1136/jnnp-2016-314863.

GAD65 neurological autoimmunity.

McKeon A, Tracy JA

Muscle & nerve 2017; (56(1)):15-27 doi:10.1002/mus.25565.

Dysphagia in Friedreich Ataxia.

Keage MJ, Delatycki MB, Gupta I, et al.

Dysphagia 2017; (32(5)):626-635 doi:10.1007/s00455-017-9804-4.

Autoimmune Neurology of the Central Nervous System.

Tobin WO, Pittock SJ

Continuum (Minneapolis, Minn.) 2017; (23(3, Neurology of Systemic Disease)):627-653 doi:10.1212/CON.0000000000000487.

From dizziness to severe ataxia and dysarthria: New cases of anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia suggest a broad clinical spectrum.

Wallwitz U, Brock S, Schunck A, et al.

Journal of neuroimmunology 2017; (309()):77-81 doi:10.1016/j.jneuroim.2017.05.011.

Cerebellopathy secondary to anti-peroxidase antibody-mediated toxicity. A special case of Hashimoto encephalopathy.

Álvarez Bravo G, Yusta Izquierdo A, Carvalho Monteiro G, Sánchez I

Journal of neuroimmunology 2017; (312()):1-3 doi:10.1016/j.jneuroim.2017.08.007.

Paraneoplastic Disorders.

Lancaster E

Continuum (Minneapolis, Minn.) 2017; (23(6, Neuro-oncology)):1653-1679 doi:10.1212/CON.0000000000000542.

Time Is Cerebellum.

Mitoma H, Manto M, Hampe CS

Cerebellum (London, England) 2018; (17(4)):387-391 doi:10.1007/s12311-018-0925-6.

[Cerebellar Ataxia and Autoantibodies].

Nanri K, Yoshikura N, Kimura A, et al.

Brain and nerve = Shinkei kenkyu no shinpo 2018; (70(4)):371-382 doi:10.11477/mf.1416201010.

Immune-mediated ataxias.

Joubert B, Rostásy K, Honnorat J

Handbook of clinical neurology 2018; (155()):313-332 doi:10.1016/B978-0-444-64189-2.00021-4.

Endocrine disorders and the cerebellum: from neurodevelopmental injury to late-onset ataxia.

Manto M, Hampe CS

Handbook of clinical neurology 2018; (155()):353-368 doi:10.1016/B978-0-444-64189-2.00023-8.

Autoimmune septin-5 cerebellar ataxia.

Honorat JA, Lopez-Chiriboga AS, Kryzer TJ, et al.

Neurology(R) neuroimmunology & neuroinflammation 2018; (5(5)):e474 doi:10.1212/NXI.0000000000000474.

Immune-mediated Cerebellar Ataxias: Practical Guidelines and Therapeutic Challenges.

Mitoma H, Manto M, Hampe CS

Current neuropharmacology 2019; (17(1)):33-58 doi:10.2174/1570159X16666180917105033.

TRIM9 and TRIM67 Are New Targets in Paraneoplastic Cerebellar Degeneration.

Do LD, Gupton SL, Tanji K, et al.

Cerebellum (London, England) 2019; (18(2)):245-254 doi:10.1007/s12311-018-0987-5.

Acute ataxia in paediatric emergency departments: a multicentre Italian study.

Garone G, Reale A, Vanacore N, et al.

Archives of disease in childhood 2019; (104(8)):768-774 doi:10.1136/archdischild-2018-315487.

Acute cerebellar ataxia: differential diagnosis and clinical approach.

Pedroso JL, Vale TC, Braga-Neto P, et al.

Arquivos de neuro-psiquiatria 2019; (77(3)):184-193 doi:10.1590/0004-282X20190020.

Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2.

Ruiz-García R, Martínez-Hernández E, Joubert B, et al.

Neurology(R) neuroimmunology & neuroinflammation 2020; (7(2)) doi:10.1212/NXI.0000000000000658.

Autoimmune Vestibulocerebellar Syndromes.

Narayan RN, McKeon A, Fife TD

Seminars in neurology 2020; (40(1)):97-115 doi:10.1055/s-0039-3402061.

Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment.

Muñoz-Lopetegi A, de Bruijn MAAM, Boukhrissi S, et al.

Neurology(R) neuroimmunology & neuroinflammation 2020; (7(3)) doi:10.1212/NXI.0000000000000696.

Diagnostic Criteria for Primary Autoimmune Cerebellar Ataxia-Guidelines from an International Task Force on Immune-Mediated Cerebellar Ataxias.

Hadjivassiliou M, Graus F, Honnorat J, et al.

Cerebellum (London, England) 2020; (19(4)):605-610 doi:10.1007/s12311-020-01132-8.

GAD antibodies in neurological disorders - insights and challenges.

Graus F, Saiz A, Dalmau J

Nature reviews. Neurology 2020; (16(7)):353-365 doi:10.1038/s41582-020-0359-x.

Treatment of Primary Autoimmune Cerebellar Ataxia with Mycophenolate.

Hadjivassiliou M, Grunewald RA, Shanmugarajah PD, et al.

Cerebellum (London, England) 2020; (19(5)):680-684 doi:10.1007/s12311-020-01152-4.

Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.

Yshii L, Bost C, Liblau R

Frontiers in immunology 2020; (11()):991 doi:10.3389/fimmu.2020.00991.

[Differential Diagnosis of Idiopathic Cerebellar Ataxia].

Kuwabara S

Brain and nerve = Shinkei kenkyu no shinpo 2020; (72(9)):969-972 doi:10.11477/mf.1416201630.

Treatment-responsive primary autoimmune cerebellar ataxia in a patient with IgG and IgM anticerebellar antibodies.

Jaffe SL, Carlson NG, Peterson LK, Greenlee JE

European journal of neurology 2021; (28(5)):1771-1773 doi:10.1111/ene.14659.

Indirect immunofluorescent assay as an aid in the diagnosis of suspected immune mediated ataxias.

Hadjivassiliou M, Wild G, Shanmugarajah P, et al.

Cerebellum & ataxias 2021; (8(1)):6 doi:10.1186/s40673-021-00129-1.

[Adult-onset ataxias].

Jacobi H, Minnerop M

Der Nervenarzt 2021; (92(4)):379-389 doi:10.1007/s00115-021-01099-9.

Clinical Spectrum, Therapeutic Outcomes and Prognostic predictors in Paraneoplastic Neurological Syndromes - Experiences from a Tertiary Care Center in India.

Vijayaraghavan A, Alexander PT, Nair AV, et al.

Annals of Indian Academy of Neurology 2021; (24(1)):32-39 doi:10.4103/aian.AIAN_975_20.

Cerebellar ataxia and myeloradiculopathy associated with AP3B2 antibody: a case report and literature review.

Mange L, Haitao R, Lixin Z, et al.

Journal of neurology 2021; (268(11)):4163-4169 doi:10.1007/s00415-021-10496-8.

Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.

Graus F, Vogrig A, Muñiz-Castrillo S, et al.

Neurology(R) neuroimmunology & neuroinflammation 2021; (8(4)) doi:10.1212/NXI.0000000000001014.

Recognition and management of rapid-onset gluten ataxias: case series.

Newrick L, Hoggard N, Hadjivassiliou M

Cerebellum & ataxias 2021; (8(1)):16 doi:10.1186/s40673-021-00139-z.

Autoimmune Neurogenic Dysphagia.

Stathopoulos P, Dalakas MC

Dysphagia 2022; (37(3)):473-487 doi:10.1007/s00455-021-10338-9.

Neurological Autoimmunity Associated With Homer-3 Antibody: A Case Series From China.

Liu M, Ren H, Fan S, et al.

Neurology(R) neuroimmunology & neuroinflammation 2021; (8(6)) doi:10.1212/NXI.0000000000001077.

Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia.

Damato V, Papi C, Spagni G, et al.

European journal of neurology 2022; (29(2)):564-572 doi:10.1111/ene.15161.

Anti-Tr/DNER Antibody-Associated Cerebellar Ataxia: a Systematic Review.

Campana IG, Silva GD

Cerebellum (London, England) 2022; (21(6)):1085-1091 doi:10.1007/s12311-021-01346-4.

Update on Paraneoplastic Cerebellar Degeneration.

Loehrer PA, Zieger L, Simon OJ

Brain sciences 2021; (11(11)) doi:10.3390/brainsci11111414.

Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration: Case Series and Review of Literature.

Chatham M, Niravath P

Cureus 2021; (13(12)):e20203 doi:10.7759/cureus.20203.

Cerebellar long-term depression and auto-immune target of auto-antibodies: the concept of LTDpathies.

Mitoma H, Honnorat J, Yamaguchi K, Manto M

Molecular biomedicine 2021; (2(1)):2 doi:10.1186/s43556-020-00024-x.

SEZ6L2 Antibody-Associated Cerebellar Ataxia Responsive to Sequential Immunotherapy.

Mehdiyeva A, Hietaharju A, Sipilä J

Neurology(R) neuroimmunology & neuroinflammation 2022; (9(2)) doi:10.1212/NXI.0000000000001131.

Advances in the Pathogenesis of Auto-antibody-Induced Cerebellar Synaptopathies.

Mitoma H, Manto M

Cerebellum (London, England) 2023; (22(1)):129-147 doi:10.1007/s12311-021-01359-z.

Paraneoplastic and Other Autoimmune Encephalitides: Antineuronal Antibodies, T Lymphocytes, and Questions of Pathogenesis.

Greenlee JE, Carlson NG, Abbatemarco JR, et al.

Frontiers in neurology 2021; (12()):744653 doi:10.3389/fneur.2021.744653.

Multimodal Mobility Assessment Predicts Fall Frequency and Severity in Cerebellar Ataxia.

Schniepp R, Huppert A, Decker J, et al.

Cerebellum (London, England) 2023; (22(1)):85-95 doi:10.1007/s12311-021-01365-1.

Immune-Mediated Cerebellar Ataxia Associated With Neuronal Surface Antibodies.

Jia Y, Li M, Li D, et al.

Frontiers in immunology 2022; (13()):813926 doi:10.3389/fimmu.2022.813926.

Oligoclonal bands: clinical utility and interpretation cues.

Carta S, Ferraro D, Ferrari S, et al.

Critical reviews in clinical laboratory sciences 2022; (59(6)):391-404 doi:10.1080/10408363.2022.2039591.

Autoimmune Cerebellar Ataxia: Etiology and Clinical Characteristics of a Case Series from China.

Liu M, Ren H, Zhu Y, et al.

Cerebellum (London, England) 2023; (22(3)):379-385 doi:10.1007/s12311-022-01412-5.

Unravelling the etiology of sporadic late-onset cerebellar ataxia in a cohort of 205 patients: a prospective study.

Bogdan T, Wirth T, Iosif A, et al.

Journal of neurology 2022; (269(12)):6354-6365 doi:10.1007/s00415-022-11253-1.

Cerebellar Ataxia With Anti-DNER Antibodies: Outcomes and Immunologic Features.

Peter E, Do LD, Hannoun S, et al.

Neurology(R) neuroimmunology & neuroinflammation 2022; (9(5)) doi:10.1212/NXI.0000000000200018.

Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with EGFR-mutated NSCLC: a case report.

Pozas J, Albarrán-Fernández V, González-Campo L, et al.

Translational lung cancer research 2022; (11(7)):1497-1502 doi:10.21037/tlcr-21-989.

Case report and literature analysis: Autoimmune cerebellar ataxia associated with homer-3 antibodies.

Wu Q, Gong B, Jiang A, Qin X

Frontiers in neurology 2022; (13()):951659 doi:10.3389/fneur.2022.951659.

Treatable Ataxias: How to Find the Needle in the Haystack?

Stezin A, Pal PK

Journal of movement disorders 2022; (15(3)):206-226 doi:10.14802/jmd.22069.

Neurodegenerative Cerebellar Ataxia.

Rosenthal LS

Continuum (Minneapolis, Minn.) 2022; (28(5)):1409-1434 doi:10.1212/CON.0000000000001180.

A Systematic Review on Anti-Yo/PCA-1 Antibody: Beyond Cerebellar Ataxia in Middle-Aged Women with Gynecologic Cancer.

Mendes NT, Ronchi NR, Silva GD

Cerebellum (London, England) 2023; (22(6)):1287-1292 doi:10.1007/s12311-022-01492-3.

Evaluation of Cerebellar Ataxic Patients.

Radmard S, Zesiewicz TA, Kuo SH

Neurologic clinics 2023; (41(1)):21-44 doi:10.1016/j.ncl.2022.05.002.

Immunotherapies for the Effective Treatment of Primary Autoimmune Cerebellar Ataxia: a Case Series.

Li J, Deng B, Song W, et al.

Cerebellum (London, England) 2023; (22(6)):1216-1222 doi:10.1007/s12311-022-01496-z.

Anti-neurochondrin antibody as a biomarker in primary autoimmune cerebellar ataxia-a case report and review of the literature.

Schwarzwald A, Salmen A, León Betancourt AX, et al.

European journal of neurology 2023; (30(4)):1135-1147 doi:10.1111/ene.15648.

Favorable Outcome with Intravenous Immunoglobulin Therapy in Late-Onset Anti-mGluR1 Encephalitis: A Case Report and Literature Review.

Sakashita K, Nishida K, Takenaka Y, et al.

Case reports in neurology 2022; (14(3)):494-500 doi:10.1159/000526632.

Autoimmune Cerebellar Ataxia Associated with Anti-Glutamate Receptor δ2 Antibodies: a Rare but Treatable Entity.

Khatib L, Do LD, Benaiteau M, et al.

Cerebellum (London, England) 2024; (23(1)):260-266 doi:10.1007/s12311-023-01523-7.

Diagnostic criteria for autoimmune encephalitis: utility and pitfalls for antibody-negative disease.

Dalmau J, Graus F

The Lancet. Neurology 2023; (22(6)):529-540 doi:10.1016/S1474-4422(23)00083-2.

Utility of Protein Microarrays for Detection of Classified and Novel Antibodies in Autoimmune Neurologic Disease.

McKeon A, Lesnick C, Vorasoot N, et al.

Neurology(R) neuroimmunology & neuroinflammation 2023; (10(5)) doi:10.1212/NXI.0000000000200145.

A retrospective study of autoimmune cerebellar ataxia over a 20-year period in a single institution.

Kudo A, Yaguchi H, Tanaka K, et al.

Journal of neurology 2024; (271(1)):553-563 doi:10.1007/s00415-023-11946-1.

[A case of Seizure-related 6 homolog like 2 (Sez6l2) antibody-associated autoimmune cerebellar ataxia].

Matsuyama Y, Satake M, Abe M, et al.

Rinsho shinkeigaku = Clinical neurology 2023; (63(10)):665-671 doi:10.5692/clinicalneurol.cn-001869.

Favorable Outcomes in a Case of Non-paraneoplastic DNER Ataxia Treated with Immunotherapy.

Duan RN, Si WY, Cao LL

Cerebellum (London, England) 2024; (23(4)):1697-1701 doi:10.1007/s12311-023-01636-z.

Recent Advances in Immune-Mediated Cerebellar Ataxias: Pathogenesis, Diagnostic Approaches, Therapies, and Future Challenges-Editorial.

Manto M, Mitoma H

Brain sciences 2023; (13(12)) doi:10.3390/brainsci13121626.

Prognostic and relapsing factors of primary autoimmune cerebellar ataxia: a prospective cohort study.

Liu M, Ren H, Wang L, et al.

Journal of neurology 2024; (271(3)):1072-1079 doi:10.1007/s00415-023-12128-9.

Effectiveness and cost of integrated cognitive and balance training for balance and falls in cerebellar ataxia: a blinded two-arm parallel group RCT.

Winser SJ, Chan AYY, Whitney SL, et al.

Frontiers in neurology 2023; (14()):1267099 doi:10.3389/fneur.2023.1267099.

Autoantibodies against eukaryotic translation elongation factor 1 delta in two patients with autoimmune cerebellar ataxia.

Guo L, Ren H, Fan S, et al.

Frontiers in immunology 2023; (14()):1289175 doi:10.3389/fimmu.2023.1289175.

[Blood-brain barrier breakdown and autoimmune cerebellar ataxia].

Shimizu F

Rinsho shinkeigaku = Clinical neurology 2024; (64(3)):148-156 doi:10.5692/clinicalneurol.cn-001932.

Paraneoplastic movement disorders.

McKeon A, Tracy J

Handbook of clinical neurology 2024; (200()):211-227 doi:10.1016/B978-0-12-823912-4.00004-9.

Paraneoplastic neurologic syndrome associated with gynecologic and breast malignancies.

Peter E, Honnorat J, Desestret V

Handbook of clinical neurology 2024; (200()):409-417 doi:10.1016/B978-0-12-823912-4.00014-1.

Immune Ataxias: The Continuum of Latent Ataxia, Primary Ataxia and Clinical Ataxia.

Manto M, Mitoma H

Journal of integrative neuroscience 2024; (23(4)):79 doi:10.31083/j.jin2304079.

Recent advances in diagnosis of immune-mediated cerebellar ataxias: novel concepts and fundamental questions on autoimmune mechanisms.

Mitoma H, Manto M

Journal of neurology 2024; (271(10)):7046-7053 doi:10.1007/s00415-024-12596-7.

Autoimmune Movement Disorders.

Balint B

Continuum (Minneapolis, Minn.) 2024; (30(4)):1088-1109 doi:10.1212/CON.0000000000001455.

Roles of CDR2 and CDR2L in Anti-Yo Paraneoplastic Cerebellar Degeneration: A Literature Review.

Martínez Lozada PS, Mancero Montalvo R, Iturralde Carrillo A, et al.

International journal of molecular sciences 2024; (26(1)) doi:10.3390/ijms26010070.

Demystifying the Etiology of ILOCA in the Genomic Era: A Narrative Review.

Novis LE, Silva TYT, Pedroso JL, Barsottini OGP

Cerebellum (London, England) 2025; (24(2)):45 doi:10.1007/s12311-025-01798-y.

GAD antibodies in neurological disease: a critical evaluation of the utility and treatment implications of GAD antibodies in clinical practice.

Brown RL, Thomas-Black G, Garcia-Moreno H, et al.

Journal of neurology 2025; (272(3)):222 doi:10.1007/s00415-025-12926-3.

FDG-PET in Autoimmune Cerebellar Ataxia: Clinical Correlation and Diagnostic Superiority Over MRI.

Liu M, Li Q, Mao G, et al.

Cerebellum (London, England) 2025; (24(5)):130 doi:10.1007/s12311-025-01888-x.

Progress and challenges in sporadic late-onset cerebellar ataxias.

Wirth T, Faber J, Depienne C, et al.

Nature reviews. Neurology 2025; (21(12)):687-705 doi:10.1038/s41582-025-01136-0.

Anti-Glutamic Acid Decarboxylase 65 (GAD65) Antibodies and Neurological Syndromes.

Mohammadzadeh O, Fahimzadeh N, Elhami F, Shobeiri SS

The journal of gene medicine 2025; (27(10)):e70039 doi:10.1002/jgm.70039.

Characteristics and prognosis of PCA-1 (anti-Yo) autoimmunity and the utility of the Brief Ataxia Rating Scale in a seropositive cerebellar ataxia cohort.

Cerroni S, Hoshina Y, Glenn T, et al.

Journal of neuroimmunology 2026; (410()):578812 doi:10.1016/j.jneuroim.2025.578812.

Autoimmune cerebellopyramidal syndrome as a complex form of autoimmune cerebellar ataxia: a cohort study.

Liu M, Ren H, Fan S, et al.

Frontiers in immunology 2025; (16()):1724439 doi:10.3389/fimmu.2025.1724439.

A case of Homer-3 IgG cerebellar ataxia & literature review of 15 reported cases.

Anissian D, Dubey D, Vorasoot N, et al.

Journal of neuroimmunology 2026; (412()):578846 doi:10.1016/j.jneuroim.2025.578846.

Paraneoplastic Neurological Syndromes: Advances and Future Perspectives in Immunopathogenesis and Management.

Dimitrov S, Tsalta-Mladenov M, Kabakchieva P, et al.

Antibodies (Basel, Switzerland) 2026; (15(1)) doi:10.3390/antib15010008.

Autoimmune cerebellar ataxia with anti-Homer3 antibodies associated with herpesvirus infection: a case report and literature review.

Song DJ, Dong R, Liu YM, et al.

Frontiers in immunology 2025; (16()):1709326 doi:10.3389/fimmu.2025.1709326.

A case of autoimmune cerebellar ataxia associated with anti-neurochondroitin antibody.

Yang J, Xu Y, Huang Y

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026; (47(5)).

Anti-Sez6L2 antibody-associated autoimmune cerebellar ataxia: a rare case with implications of rituximab therapy.

Gao Y, Duan R

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026; (47(5)).

Suspected autoimmune cerebellar ataxia: Predictors of immunotherapy response and diagnosis reclassification to neurodegenerative disease.

Nakamura N, Ii Y, Hirata Y, et al.

Journal of the neurological sciences 2026; (488()):126048 doi:10.1016/j.jns.2026.126048.

Cerebellar Involvement in Immune-Mediated Pediatric Acute Ataxia: Clinical Spectrum, MRI Findings, and Predictors of MOG Antibody Positivity.

Zhao Q, Gao C, Li B, et al.

Cerebellum (London, England) 2026; (25(4)).

Anti-Ma2 Antibody-Associated Paraneoplastic Cerebellar Degeneration Mimicking the Cerebellar Ataxic Subtype of Hashimoto's Encephalopathy: A Case Report.

Okitsu M, Nojiri S, Kawazoe T, et al.

Case reports in neurological medicine 2026; (2026()):1445118 doi:10.1155/crnm/1445118.

Paraneoplastic Neurological Syndromes in Ovarian Cancer: Case Report and Narrative Review for Diagnostic and Clinical Implications.

Restaino S, Gomba B, Golitsyna Y, et al.

Healthcare (Basel, Switzerland) 2026; (14(13)) doi:10.3390/healthcare14131943.

Clinical approach to neurological paraneoplastic syndromes.

Anderson NE

Internal medicine journal 2026; (56(8)):1314-1322 doi:10.1111/imj.70500.

Non-paraneoplastic Autoimmune Cerebellar Ataxia with Sensory Ataxia Associated with the Anti-Ca/ARHGAP26 Antibody: A Case Report.

Zhang H, Duan X, Zheng W, et al.

Cerebellum (London, England) 2026; (25(5)).